Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 Ansichten
• 07/18/23
0
0
Einbetten
administrator
Abonnenten
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Zeig mehr
Facebook Kommentare
SORT BY-
Beste Kommentare
-
Neueste Kommentare